<DOC>
	<DOC>NCT02743416</DOC>
	<brief_summary>The STROKESTOP II study is a proposed study to determine if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.</brief_summary>
	<brief_title>Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Individuals born 1940 and 1941 residing in Stockholm at the time of inclusion Not fulfilling the inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Screening</keyword>
	<keyword>Stroke prevention</keyword>
	<keyword>Cost effectiveness</keyword>
</DOC>